A cancer scare helped encourage stem cell researcher Paul Knoepfler to become an outspoken watchdog over his field.
Carl Costas
By Kelly ServickAug. 3, 2017 , 9:00 AM
SACRAMENTOBack in his lab after a week of vacation, Paul Knoepfler slogs through backlogged emails: A 71-year-old woman with arthritic knees would like to know whether a stem cell clinic she researched can give her relief. The parents of a 12-year-old with a degenerative eye disease wonder whether there's any hope of averting blindness with a stem cell injection. "Kindly apprise us of expenses and chance of success," they ask.
Knoepfler, though housed in the Shriners Hospitals for Children here, isn't a physician. And his University of California (UC), Davis, lab doesn't study arthritis or eye disease, nor does he have any experience developing a stem cell therapy. He mostly uses stem cells to study cancer-causing gene mutations. But thanks to The Niche, a blog he has run since 2010, Knoepfler has become an unlikely authorityand a dogged voice of cautionon the clinical use of stem cells.
The blog, which now averages more than 4000 daily visits, has elevated him from an obscure bench scientist to an international spokesperson on all things stem cell. "It's one of the major sources of information [for the] layperson, and also for stem cell researchers," says Jeanne Loring of Scripps Research Institute in San Diego, California, an occasional commenter and guest writer on the blog.
It also has turned Knoepfler, a softspoken, unimposing presence in person, into a divisive figure. He has sounded the alarm on hundreds of U.S. physicians and clinics advertising stem cells to treat everything from sore knees to spinal cord injury. These offerings haven't been through the approval process at the U.S. Food and Drug Administration (FDA), and most aren't supported by evidence from randomized clinical trials.
"They were just saying, Screw the rules, we're just going to set up shop and put up a website and start injecting people with stem cells,'" says Knoepfler, who co-wrote a paper last year documenting the scope of this industry. "I saw that as a threat, first to patients, but to the field as well."
Stem cell researchers largely applaud his efforts. "He's been a reliable voice of reason in the field," says George Daley, a stem cell researcher at Boston Children's Hospital and dean of Harvard Medical School in Boston. Academics are "often more comfortable being provincial and insular, and not mixing it up in the public debates."
But even people who have expressed concern about predatory and fraudulent clinics contend Knoepfler has sometimes painted potential stem cell therapies with too broad a brush. "There are clinicians in the United States that are practicing forms of regenerative medicine that are legal and that are having good results for their patients," says Bernard Siegel, executive director of the nonprofit Regenerative Medicine Foundation in Wellington, Florida. "We can't tar everyone."
Siegel says he admires Knoepfler, and his foundation honored the blogger with its national advocacy award in 2013. But in Siegel's view, Knoepfler has at times acted as "almost a bit of a societal scold."
On The Niche's discussion thread, patients who believe they have benefited from unapproved stem cell treatments are harsher. "You and I will never agree on this issue," wrote one commenter, Barbara Hanson, who has sought stem cell treatment overseas for chronic obstructive pulmonary disease and runs an online forum for patients, in a discussion about the value of FDA approval. "I have experienced a much better quality of life after having stem cell treatment than I could ever have expected from prescription medications and conventional treatment."
Seven years into the conversation, Knoepfler accepts criticism in stride. But with FDA looking unlikely to tighten its grip on such clinics, and strong pressure from some patients, advocates, and companies to keep stem cell treatments outside regulators' grasp, he admits the impact of his outreach is hard to measure. "A few individuals can't really necessarily rein in a whole industry."
Paul Knoepfler's blog, The Niche, steadily gained readers in its early years, but saw a spike in 2014 with his skeptical coverage of stimulus-triggered acquisition of pluripotency (STAP) stem cell claims.
(Graphic) G. Grulln/science; (Data) Paul Knoepfler
Knoepfler's fascination with stem cells grew out of science, but his willingness to speak out started with a life-changing personal event. A college English major, he didn't commit to science until he landed a postgraduation job as a research technician at UC San Diego, where his wife was starting medical school. "Being in the lab setting felt like I was at home," he says.
While working on a doctorate there and a postdoc at the Fred Hutchinson Cancer Research Center in Seattle, Washington, Knoepfler explored the proteins and genes that act up in some childhood cancers. To understand why variations in the gene MYC and its relatives lead to childhood brain tumors, Knoepfler realized he would have to detail their normal role in the growth and differentiation of neural stem cells.
Just as he set out to establish his own lab, the state of California launched a grand experiment in stem cell funding. Motivated in part by then-President George W. Bush's ban on federal funding for embryonic stem (ES) cell research, which antiabortion groups opposed, California voters approved the $3 billion California Institute for Regenerative Medicine (CIRM). In 2006, a $2 million "new faculty" grant from CIRM helped get Knoepfler's UC Davis lab off the ground.
It had been running for 3 years when, at age 42, he was diagnosed with prostate cancer and given roughly 50-50 survival odds. Knoepfler found himself a patient at the same cancer center he frequented for research meetings and seminars. "This time, I walked straight past the auditorium for the clinic. That was a freaky moment."
Surgery led to a remission that has now lasted for 7 years. But the medical scare emboldened him "to try to expand how I had impact, beyond just the pure science," he says. Weeks after the operation, Knoepfler published the first official post on The Niche, named after a defunct stem cell blog once hosted on Nature.com that he admired. (Stem cells often reside and grow in specific niches in the body, such as bone marrow, which houses blood-forming cells.)
Early on, Knoepfler was an impassioned and partisan advocate for ES cell research. Many Republicans "are in favor of executing prisoners who might be innocent, taking away women's rights, cutting aid to poor children, eliminating Social Security," he wrote after Mississippi lawmakers introduced an amendment to give embryos constitutional protections, "but when it comes to fertilized eggs or few-days-old blastocysts, they start carrying pitchforks and torches."
As the threat to ES cell research began to feel less serious under former President Barack Obama's administration, Knoepfler's attention shifted. His periodic Google searches for "stem cells" began to turn up unfamiliar treatment centers in the United States advertising poorly validated therapies. Many clinics isolated adult stem cells from a patient's own fat or bone marrow and reinjected them, promising to heal injured joints, rejuvenate aging skin, or even repair damage from neurological disorders and autoimmune disease.
Recently, Knoepfler and bioethicist Leigh Turner of the University of Minnesota in Minneapolis set out to compile U.S. stem cell clinics marketing directly to consumers online. In a paper in Cell Stem Cell, they revealed a marketplace of 351 businesses operating at 570 clinics. "That was a tremendous piece of work," says David Jensen, a retired newspaper journalist in Paso Robles, California, who runs a blog monitoring CIRM. "You could see it was a problem if you looked out your window. The question was how big it is."
Knoepfler believes that new stem cell treatments will eventually help patients, but he has long fretted about their safety. In 2012, his team published a paper pointing out similarities between tumor cells and induced pluripotent stem (iPS) cellsadult cells reprogrammed to a more primitive state in the lab. In part because iPS cells don't face religious objections, they are an appealing alternative to ES cells. But the paper concluded that iPS cells' potential for cancerous growth could stand in the way of using them therapeutically.
The adult stem cells used in most of the emerging clinics didn't undergo the same reprogramming process, but Knoepfler still worried about their potential for uncontrolled growth. "I guess I just had this deep concern that someone was going to get cancer, maybe because of my own experience with cancer, in retrospect."
Knoepfler acknowledges that few stem cell-induced cancers and other serious side effects have been reported. But he maintains that the risk is still there, noting the case of stroke patient Jim Gass, who ended up with a tumor along his spine after a series of stem cell injections at clinics outside the United States. A report this year in The New England Journal of Medicine also documented three women who were blinded after a Florida clinic injected them with stem cells to treat macular degeneration. And even patients not physically harmed might spend thousands of dollars on useless treatments that insurers often refuse to cover.
At first, Knoepfler thought FDA would crack down on the emerging industryan expectation he now calls nave. The only FDA-approved stem cell therapies involve transplants of umbilical cord blood-derived stem cells for blood cancers and certain metabolic and immune disorders. But the agency classifies other uses of stem cells as medical procedures and exempts them from its drug approval process, provided they meet certain criteria, including "minimal manipulation" of the cells and "homologous use"using the cells for the same function they naturally perform in the body. Some uncertainty remains about which products are exemptedparticularly when it comes to fat-derived stem cells. Draft guidances FDA issued in 2014 and 2015 seemed to narrow the set of exempted therapies, but those have yet to be finalized.
Meanwhile, Knoepfler pursues his own grassroots effort with unlikely passion. "He's a sweetheart," Jensen says. "Personally, I find him sort of shy and diffident sometimes," but Knoepfler "doesn't shy away from contact with the mainstream media." He has picked apart stem cell claims that seem too good to be true, requested details from clinics, and complained about uncritical press coverage of treatments.
Even after a recent redesign of The Niche, Knoepfler's corner of the internet feels homespun and unadorned. He often illustrates his posts with corny clip art, appropriated Hollywood movie posters ("A Nightmare on Stem Street"), and cartoons he draws himself. The blog yo-yos between audiences, dissecting a technical research paper one day, raising questions about a celebrity's stem cell boob job the next. Its most visited page in the past year is a Spanish translation of his layperson-friendly explainer, "What are stem cells?"
In 2014, Knoepfler found himself fielding midnight calls from Japanese reporters after he blogged his doubts about a paper from a Kobe-based research team describing stimulus-triggered acquisition of pluripotency (STAP) stem cells, allegedly created from adult cells by simple measures such as exposure to acid. He published some of the earliest skepticism of the claim, which swiftly fell apart through failed replication attempts, a misconduct investigation, and the paper's retraction. Knoepfler chronicled the downfall of STAP stem cells blow by blow.
Other moves drew more criticism. Knoepfler took to The Sacramento Bee last June to decry what he saw as a dangerous shift in CIRM's agenda. In a Fox News oped, CIRM's then-President C. Randal Mills and Senator Bill Frist (R-TN) criticized FDA's regulatory process as too rigid. The comments came as the Senate considered legislation that would let FDA conditionally approve stem cell therapies without largescale clinical trials. CIRM "should refocus its efforts on the science and medicine of stem cells," Knoepfler wrote, "instead of lobbying for high-risk weakening of federal stem cell oversight."
The affront to the head of a major funding organization that had supported Knoepfler's own lab struck some colleagues as reckless. "I advised him not to do it," says Loring, adding, "it doesn't mean I agreed with [Mills]."
Asked about Knoepfler's criticism the next week, Mills called him "fairly self-interested" in his push for more basic research and suggested that critics of FDA reform "live with a horrible disease" before defending the agency's slow and expensive process for approving new treatments.
Knoepfler's unyielding skepticism has also turned some patients against him. In a three-part series of posts this spring, he questioned the ethics of a center at Northwestern University's Feinberg School of Medicine in Chicago, Illinois, that is attempting to treat autoimmune diseases such as multiple sclerosis (MS) by eliminating patients' immune cells and then using their bone marrow stem cells to replenish them. The principal investigator, Richard Burt, has run clinical trials, but has also provided treatment outside of trials under an FDA-sanctioned protocol known as expanded access.
After hearing that some MS patients were asked to pay as much as $150,000 to participate in a trial or receive off-study treatment, Knoepfler took to his blog. Although careful not to equate Burt's operation with for-profit clinics, Knoepfler suggested that testimonials on the center's website painted too rosy a picture of the experimental therapy and that its patient handbook encouraged fundraising efforts that might force patients to share private health information.
"It was astonishing, what he wrote," says Heather Burke of Orlando, Florida, who credits treatment at Northwestern with putting her MS into permanent remission and runs a Facebook group for patients. She says Burt tells patients that the procedure is potentially fatal and never promises improvements in their symptoms. Knoepfler's suggestion that Northwestern endorses fundraising is unfair, she adds, because for most patients, the procedure is fully covered by insurance. (Burt declined a request for comment.)
Burke shares Knoepfler's concerns about stem cell clinics that peddle shoddy science. But "Northwestern is not a popsicle stand in Mexico," she says. "When you have bloggers like Paul putting things out there like this, the only thing that they're doing is halting a possible really big breakthrough for treatments for MS."
One patient threatened to file an ethics complaint with his university. Others have accused Knoepfler of being a shill for Big Pharma, intent on suppressing alternatives to traditional drugs. (Knoepfler says he receives no funding from pharmaceutical companies.)
Knoepfler's online jabs at high-profile figures, companies, and doctors have never led to a libel lawsuitthough he says there have been a few threats. He has had tenure since 2011, and higher-ups at the university have never reprimanded him for voicing his opinions online, he says. But the stream of negativity has made him question how much longer he will continue blogging, even if he has no immediate plans to stop. "It takes a certain amount of energy just to deal with that."
He also admits that "I haven't necessarily made much headway" in convincing advocates of unfettered stem cell access that careful oversight is important, too. In recent years, nearly 40 states have passed controversial "right to try" laws, meant to allow dying patients easier access to experimental treatments without FDA oversight. And in June, Texas enacted a law that allows clinics to offer stem cell interventions without the testing and approval required under federal law. Knoepfler has predicted the change will be a boon to predatory clinics.
Still, he believes his handful of weekly email exchanges with conflicted patients is a chance to make a difference. He encourages them to get advice from their doctors, then explains why he's skeptical of approaches not proven in randomized trials. Some, he knows, will decide to go through with treatments anyway. Rarely do they write back to tell him about their decision. "That's kind of a hard part for me," he says. "I don't know the end of the story."
- Politics of Stem Cell Research - May 7th, 2011 [May 7th, 2011]
- Obama Ends Funding Ban for Stem Cell Research - May 8th, 2011 [May 8th, 2011]
- Stem Cell Research: A Father's Fight - May 10th, 2011 [May 10th, 2011]
- Human Embryonic stem cell research - May 11th, 2011 [May 11th, 2011]
- Frost Over The World - Stem Cell Research and Turkey -26 Oct - May 20th, 2011 [May 20th, 2011]
- McCain Favors Embryonic Stem Cell Research - May 20th, 2011 [May 20th, 2011]
- US divided over stem cell research reversal - 09 Mar 09 - May 21st, 2011 [May 21st, 2011]
- The Politics and Promise of Stem Cell Research - May 22nd, 2011 [May 22nd, 2011]
- Inside Story - Obama to end stem cell research ban - March 9 - Part1 - May 30th, 2011 [May 30th, 2011]
- Cardiovascular Therapies: Spotlight on Stem Cell Research - Douglas Boyd - June 3rd, 2011 [June 3rd, 2011]
- The Human Embryo and Embryonic Stem Cell Biology: Spotlight on Stem Cell Research - June 3rd, 2011 [June 3rd, 2011]
- US appeals court lifts stem cell research ban - June 7th, 2011 [June 7th, 2011]
- Trailer for Mapping Stem Cell Research: Terra Incognita - June 9th, 2011 [June 9th, 2011]
- Politics: President Obama on Stem Cell Research - June 10th, 2011 [June 10th, 2011]
- Stem Cell Research Documentary - June 11th, 2011 [June 11th, 2011]
- TEDxSingapore - Susan Lim - Hype and hope of stem cell research - June 13th, 2011 [June 13th, 2011]
- Lou Gehrig's Disease (ALS): Spotlight on Stem Cell Research - Wrapup - June 14th, 2011 [June 14th, 2011]
- The Next Frontier in Stem Cell Research - June 17th, 2011 [June 17th, 2011]
- Robert Klein: Stem Cell Research - June 22nd, 2011 [June 22nd, 2011]
- Fibrocell Stem-Cell Wrinkle Smoother Wins FDA Clearance - June 23rd, 2011 [June 23rd, 2011]
- The Politics of Stem Cell Research - June 23rd, 2011 [June 23rd, 2011]
- A Dose of Reality on Alternative Stem Cell Treatments: What you don't know can hurt you - June 28th, 2011 [June 28th, 2011]
- Governor Tim Pawlenty Discusses Stem Cell Research - June 30th, 2011 [June 30th, 2011]
- The EU and stem cell research - July 5th, 2011 [July 5th, 2011]
- Parkinson's Disease: Spotlight on Stem Cell Research - Jeff Bronstein - July 6th, 2011 [July 6th, 2011]
- Cardiovascular Therapies: Spotlight on Stem Cell Research - Yung-Wei Chi - July 7th, 2011 [July 7th, 2011]
- Spotlight on Cancer Stem Cell Research - July 11th, 2011 [July 11th, 2011]
- A Stem Cell Story - July 12th, 2011 [July 12th, 2011]
- Bishop Blair bars support for Komen breast cancer group - July 13th, 2011 [July 13th, 2011]
- Stem Cell Research In Toronto - July 14th, 2011 [July 14th, 2011]
- Arthritis: Spotlight on Stem Cell Research - Introduction - July 14th, 2011 [July 14th, 2011]
- Huntington's Disease: Spotlight on Stem Cell Research 2007 - Han Keirstead - July 15th, 2011 [July 15th, 2011]
- TMconfUK2011-08 - Stem Cell Research in the UK - Prof Charles Ffrench-Constant - July 16th, 2011 [July 16th, 2011]
- UCSF opens stem cell research building - July 16th, 2011 [July 16th, 2011]
- HIV/AIDS: Spotlight on Stem Cell Research - John Zaia - July 17th, 2011 [July 17th, 2011]
- Deafness: Spotlight on Stem Cell Research - Ebenezer Yamoah - July 22nd, 2011 [July 22nd, 2011]
- Spotlight on Basic Stem Cell Research - Irv Weissman - July 25th, 2011 [July 25th, 2011]
- Diabetes: Spotlight on Stem Cell Research - Peter Butler - July 27th, 2011 [July 27th, 2011]
- Parkinson's Disease: Spotlight on Stem Cell Research - Arnold Kriegstein - July 27th, 2011 [July 27th, 2011]
- HIV/AIDS: Spotlight on Stem Cell Research - Loren Leeds - July 27th, 2011 [July 27th, 2011]
- Alzheimer's Disease: Spotlight on Stem Cell Research - Leeza Gibbons - August 2nd, 2011 [August 2nd, 2011]
- Geron's Embryonic Stem Cell Clinical Trial for Spinal Cord Injury - August 3rd, 2011 [August 3rd, 2011]
- The Skin Gun stem cell research - August 10th, 2011 [August 10th, 2011]
- Deafness: Spotlight on Stem Cell Research - Karen Doyle - August 10th, 2011 [August 10th, 2011]
- Stem Cell Research: Huntington's Disease - August 14th, 2011 [August 14th, 2011]
- Adult and Non-Embryonic Stem Cell Research Conference at Notre Dame - August 20th, 2011 [August 20th, 2011]
- Stemcell Research and Aging - Panel 1 - August 22nd, 2011 [August 22nd, 2011]
- Texans for Stem Cell Research Learn for Life: KXAN Coverage Aired August 16th, 2011 - August 24th, 2011 [August 24th, 2011]
- Stem Cell Research: Macular Degeneration - September 18th, 2011 [September 18th, 2011]
- Brilliant Minds - Stem Cell Research | Tomorrow Today - September 25th, 2011 [September 25th, 2011]
- Ethics of Stem Cell Research (1) - September 29th, 2011 [September 29th, 2011]
- Legal and Public Policy Dimensions of Stem Cell Research - September 29th, 2011 [September 29th, 2011]
- Stem cell symposium - October 2nd, 2011 [October 2nd, 2011]
- StemCONN 2011, The Latest in Stem Cell Research - October 6th, 2011 [October 6th, 2011]
- Arthritis: Spotlight on Stem Cell Research - Mark Genovese - October 7th, 2011 [October 7th, 2011]
- Judy Roberson: Patient advocates drive stem cell scientists - October 8th, 2011 [October 8th, 2011]
- Sam Harris - Stem Cells and Morality - October 8th, 2011 [October 8th, 2011]
- Stem Cell Research, Ethics and Religion - October 9th, 2011 [October 9th, 2011]
- Stem Cells: Fulfilling the Promise - 2011 CIRM Grantee Meeting - October 10th, 2011 [October 10th, 2011]
- The Skin Gun (Stem Cell research to replace burnt off skin. Done in 3 days!) - October 13th, 2011 [October 13th, 2011]
- Alzheimer's Stem Cell Research Patient Advocate Spotlight: The Faces of Neurodegenerative Disease - Video - October 18th, 2011 [October 18th, 2011]
- Life in the Balance: Perspectives on Stem Cell Research - Video - October 18th, 2011 [October 18th, 2011]
- Stem Cell Research Funding Halt - Video - October 19th, 2011 [October 19th, 2011]
- Vatican lending hand in adult stem cell research - Video - October 20th, 2011 [October 20th, 2011]
- First Spinal-Cord Surgery With Stem Cells - Video - October 21st, 2011 [October 21st, 2011]
- Michael J. Fox Embryonic Stem Cell Research - Video - October 22nd, 2011 [October 22nd, 2011]
- stem cell research - Video - October 22nd, 2011 [October 22nd, 2011]
- Gayle Atteberry - Cloning - November 5th, 2011 [November 5th, 2011]
- It Takes Nerve: UC Irvine - Sue - November 6th, 2011 [November 6th, 2011]
- Embryonic Stem Cell Research - Video - November 9th, 2011 [November 9th, 2011]
- Adult Stem Cell Research Far Ahead of Embryonic - Video - November 10th, 2011 [November 10th, 2011]
- Is stem cell research a growing concern .flv - Video - November 10th, 2011 [November 10th, 2011]
- Forbes Discusses Stem Cell Research - Video - November 14th, 2011 [November 14th, 2011]
- Stem Cell Research Presentation - Video - November 16th, 2011 [November 16th, 2011]
- Benedict XVI: No embryonic stem cell research - Video - November 28th, 2011 [November 28th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - A Father's Story - Video - November 30th, 2011 [November 30th, 2011]
- CIS 111 Digital Media Project - Stem Cell Research - Video - December 13th, 2011 [December 13th, 2011]
- Regenerative Medicine and Applications of Stem Cell Research - Video - December 20th, 2011 [December 20th, 2011]
- Stem Cell Research Today: Larry Goldstein - CIRM Science Writer's Seminar - Video - December 22nd, 2011 [December 22nd, 2011]
- CIRM Bridges Award: Building California's Stem Cell Research Workforce - Video - December 22nd, 2011 [December 22nd, 2011]